Article Text

Download PDFPDF

494 CO-1: A novel potent dual function anti-CD47 antibody for cancer therapy
  1. Sittana Matar,
  2. Seham Skah,
  3. Rolf Pettersen,
  4. Kjetil Hestdal and
  5. Nina Richartz
  1. Caedo Oncology, Oslo, Norway


Background CD47 is a central part of the innate immune system through its interaction with signal regulatory protein alpha (SIRPα). This interaction is known as the “don't eat me” signal which inhibits cell phagocytosis by innate immune cells.1,2 Cancer cells often evade recognition by the hosts’ immune cells through overexpression of CD47, and several anti-CD47 monoclonal antibodies (mAbs) are undergoing development to inhibit this interaction.3 Some anti-CD47 mAbs have been shown to have potential as treatment of human malignancy, but generally only in combination with other chemotherapeutic agents as their functionality primarily is due to the inhibition of the phagocytic signal.1,4 Here, we characterize CO-1, a novel bifunctional anti-CD47 mAb that is capable of eradicating cancer cells through direct induction of programmed cell death (PCD) as well as by enhancing cancer cell phagocytosis.

Methods The binding properties of CO-1 to a wide range of cancer cell lines derived from solid and hematological tumors was determined by incubating the cells to FITC-conjugated antibodies, followed by flow cytometry analysis. The induction of PCD after treatment with different anti-CD47 mAbs at different time points was determined by Annexin V staining.5

The enhancement of tumor cell phagocytosis induced by CO-1 was determined by co-culturing DiO-labelled RAW264.7 macrophages with CFSE-labelled target cell lines. Double-positive DiO-RAW264.7 and CFSE-target cells indicated phagocytosed cells.

Xenograft models were established by injecting lentivirally transduced cancer cells into NOD-scid IL2Rγnull (NSG) mice. The lentiviral vector contained sequences for firefly luciferase and enhanced green fluorescent protein.6

Results CO-1 binds to cancer cells with high efficiency and induces rapid (within 3 hours) and profound cell death in several cell lines derived from human hematological and solid tumors. No direct correlation was evident between CD47 expression and PCD response. In a xenograft model of B cell precursor acute lymphoblastic leukemia (BCP-ALL) in NSG mice, the mice were rapidly cured of their tumor even after only two injections of CO-1 as monotherapy. This demonstrates the PCD potency of CO-1 towards human tumor cells directly. Next, we determined the ability of CO-1 to block the “don't eat me” interaction and found that CO-1 potently and significantly enhanced tumor cell phagocytosis, even in cell lines that previously had responded less favorably with PCD to CO-1 treatment.

Conclusions CO-1 is a new and unique bifunctional anti-CD47 mAb that eradicates cancer cells by two mechanisms of action: 1)by direct induction of PCD, and 2)by enhancing cancer cell phagocytosis.


  1. J Huang, F Liu, C Li, X Liang, C Li, Y Liu, Z Yi, L Zhang, S Fu, Y Zeng. Role of CD47 in tumor immunity: a potential target for combination therapy. Scientific Reports 2022;12. 10.1038/s41598-022-13764-3.

  2. S Kaur, JS Isenberg, DD Roberts. CD47 (Cluster of Differentiation 47). Atlas Genet Cytogenet Oncol Haematol 2021;25:83–102.

  3. Z Jiang, H Sun, J Yu, W Tian, Y Song. Targeting CD47 for cancer immunotherapy. J Hematol Oncol 2021;14:180. 10.1186/s13045-021-01197-w.

  4. Y Huang, Y Ma, P Gao, Z Yao. Targeting CD47: the achievements and concerns of current studies on cancer immunotherapy. Journal of Thoracic Disease 2017;9:E168–E174. 10.21037/jtd.2017.02.30.

  5. I Vermes, C Haanen, H Steffens-Nakken, C Reutellingsperger. A novel assay for apoptosis Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. Journal of Immunological Methods 1995;184: 39–51.

  6. S Bomken, L Buechler, K Rehe, F Ponthan, A Elder, H Blair, CM Bacon, J Vormoor, O Heidenreich. Lentiviral marking of patient-derived acute lymphoblastic leukaemic cells allows in vivo tracking of disease progression. Leukemia 2013;27:718–721. 10.1038/leu.2012.206.

Ethics Approval The study was conducted under adherence with the Declaration of Helsinki. Animals were kept under appropriate housing conditions with food and water ad libitum. All animal experiments were approved by the Norwegian Food Safety Authorities.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.